arrow
C

Christian H. Pfob

University of Augsburg
H指数:12
被引数:845

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

P85 - ECE_3433 - Should vitamin D supplementation be recommended in hypoparathyroidism? preliminary results from a routine care trial on cellular and humoral immunity in patients with hypoparathyroidism

P85 - ECE_3433 - 维生素D补充剂是否应推荐用于甲状腺功能减退症?来自甲状腺功能减退症患者细胞和体液免疫常规护理试验的初步结果

2026-08-100
OAAI
Outcome of first-line chemotherapy for anaplastic thyroid cancer-a multicenter registry analysis

弥漫性甲状腺癌一线化疗的疗效——一项多中心登记研究

2026-01-010
PRE
Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy

多中心配对分析脾切除术后患者肽受体放射性核素治疗长期血液毒性的研究

2025-12-010
PRE
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

Karpinski, M.J.; Rahbar, K.; Bögemann, M.; Nikoukar, L.R.; Schäfers, M.; Hoberück, S.; Miederer, M.; Hölscher, T.; Rasul, S.; Miszczyk, M.; 等. 基于前列腺特异性膜抗原正电子发射断层扫描的前列腺癌风险分组更新(PPP2):一项国际多中心登记研究的成果。Eur. Urol. 2025. [Google Scholar] [CrossRef]

2025-05-020
OAAI
CCK2 Receptor Ligand [68Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [68Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer

CCK2受体配体[68Ga]Ga-DOTA-CCK-66 PET/CT在一位小细胞肺癌患者中表现优于[68Ga]Ga-DOTATOC PET/CT

2025-02-200
PRE
Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
2024-11-040
OAAI
C-X-C Motif Chemokine Receptor 4-Directed - Directed Scintigraphy Using [99mTc]Tc-Pentixatec 99m Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study
2024-09-050
PRE
Biodistribution and Radiation Dosimetry for 68Ga-DOTA-CCK-66, a Novel CCK2R-Targeting Compound for Imaging of Medullary Thyroid Cancer

用于甲状腺髓样癌成像的新型CCK2R-Targeting化合物68Ga-DOTA-CCK-66的生物分布和辐射剂量学

2024-08-020
PRE